ARCH.V - Arch Biopartners Inc.

TSXV - TSXV Delayed Price. Currency in CAD
1.1600
-0.0400 (-3.33%)
At close: 2:06PM EDT
Stock chart is not supported by your current browser
Previous Close1.2000
Open1.1900
Bid1.1500 x 0
Ask1.1600 x 0
Day's Range1.1600 - 1.1900
52 Week Range1.0500 - 1.8400
Volume4,800
Avg. Volume11,869
Market Cap68.048M
Beta (3Y Monthly)0.36
PE Ratio (TTM)N/A
EPS (TTM)-0.0620
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2000-09-13
1y Target EstN/A
  • GlobeNewswire27 days ago

    Arch Biopartners Announces Start of Phase I Human Trial for Metablok

    Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has initiated the Phase I human trial for Metablok (“LSALT peptide”), the Company’s lead drug candidate for treating acute kidney injury and other organ damage caused by inflammation. The Phase I trial, being conducted at the Alfred Hospital in Melbourne, Australia, is a double-blind, placebo-controlled, randomized, single and multiple ascending dose study to evaluate the safety and pharmacokinetic profile of Metablok in healthy participants. The Company also announced today that a shareholder of the Company exercised 50,000 warrants expiring in July, 2019 to buy 50,000 common shares of the Company for proceeds of $25,000.

  • GlobeNewswire2 months ago

    Arch Biopartners Closes Convertible Note Financing

    Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced it has closed the non-brokered, unsecured convertible note (“Note”) financing it disclosed in a press release on May 17, 2019 for net proceeds of CAD $1,000,000 (the “Offering”). The Note matures on November 22, 2019 and will be convertible, at the option of the holder, into common shares in the capital of the Company (“Common Shares”) at a price per Common Share of $1.21, in the thirty-day period prior to the maturity of the Note. The Note bears simple interest of 5% per annum, which is payable in-kind by the Company with Common Shares to be issued at then market prices for the Common Shares and subject to TSX Venture Exchange (“TSXV”) approval.

  • GlobeNewswire2 months ago

    Arch Biopartners Arranges Convertible Note Financing

    Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced it has arranged a non-brokered, unsecured convertible note (“Note”) financing for gross proceeds of CAD $1,000,000 (the “Offering”). The Note matures on November 22, 2019 and will be convertible, at the option of the holder, into common shares in the capital of the Company (“Common Shares”) at a price per Common Share of $1.21, in the thirty-day period prior to the maturity of the Note.

  • GlobeNewswire4 months ago

    Arch Biopartners Receives Approval to Perform Phase I Clincial Trial for Metablok in Australia

    Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), today announced that it has been granted approval by the Alfred Hospital Ethics Committee to perform a Phase I clinical trial for Metablok, the Company’s lead drug candidate for treating acute kidney injury and other organ damage caused by inflammation. A successful Phase I trial will be followed by a Phase II trial to investigate Metablok’s efficacy in the prevention of acute kidney injury in cardiac surgery patients.

  • GlobeNewswire5 months ago

    Arch Biopartners Awarded NRC-IRAP Funding to Further Develop Metablok Drug Program

    Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), today announced that the National Research Council – Industrial Research Assistance Program (“NRC-IRAP”) has approved funding totaling $200,000 for Arch scientists to further develop the Metablok (LSALT peptide) program. Metablok is the Company’s lead drug candidate for treating acute kidney injury and other organs damaged by inflammation. The NRC-IRAP funds will be used to advance the drug library that is now emerging at Arch as a result of the initial development of Metablok.

  • GlobeNewswire7 months ago

    Arch Biopartners Forms New Subsidiary to Pursue a Phase I Trial in Australia for Metablok (LSALT Peptide)

    Arch Biopartners Inc., (Arch or the Company) (TSX Venture: ARCH and OTCQB: ACHFF) today announced it has formed a 100% owned subsidiary in Australia, named Arch Clinical Pty Ltd, to pursue an application to perform a phase I safety trial in Australia for Metablok, the Company’s lead drug candidate for treating acute kidney injury.

  • CNW Group10 months ago

    Arch Biopartners Announces Completion of GMP Manufacturing of Metablok Vials

    TORONTO , Sept. 26, 2018  /CNW/ - Arch Biopartners Inc., (Arch or the Company) (TSX Venture: ARCH) (ACHFF) today announced that Dalton Pharma Services (Dalton) has completed the good manufacturing practice (GMP) glass vial filling stage for Metablok, the Company's lead drug candidate for preventing acute kidney injury. Over the next six to eight weeks Dalton will be completing the quality control process which will culminate with the release of a clinical drug product to be used in a phase I safety trial for Metablok.

  • CNW Group11 months ago

    Arch Biopartners Engages Dalton Pharma Services for GMP Manufacturing of Metablok

    TORONTO , Aug. 14, 2018 /CNW/ - Arch Biopartners, Inc., (Arch or the Company) (ARCH.V) (ACHFF) a portfolio-based biotechnology company, today announced it has engaged Dalton Pharma Services (Dalton) to perform the good manufacturing practice (GMP) campaign for Metablok, (LSALT peptide), the Company's drug candidate for preventing acute kidney injury. Dalton will be responsible for the GMP preparation and filling of Metablok into glass vials through to the release of a clinical drug product.